Financial Data and Key Metrics Changes - Consolidated revenue grew 13% year-over-year to $60.2 million, with telehealth revenue increasing 18% to $47.3 million [18][19] - Adjusted EBITDA increased 30% compared to the prior year, totaling $5.1 million for the third quarter [19][21] - Gross margin for the third quarter was 88%, a decline of 290 basis points year-over-year due to revenue mix [18][19] Business Line Data and Key Metrics Changes - The RexMD business added approximately 10,000 net new subscribers, rebounding from previous lows [4][17] - Weight management remains over 50% of the company's total revenue mix, although there was a slight sequential decline in subscriber base [24][25] - Demand for personalized ED medications represented 25% of all new ED prescriptions on the RexMD platform [10] Market Data and Key Metrics Changes - LifeMD is positioned to be a leading virtual destination for high-quality care, with over 130 million Americans eligible for treatment [9] - The company expects to offer oral GLP-1 medications, which could significantly broaden access and reshape the market landscape [9][56] Company Strategy and Development Direction - Strategic priorities for 2026 include accelerating growth in weight management, scaling women's and behavioral health businesses, and launching a unified LifeMD platform [6][15] - The company aims to leverage collaborations with Novo Nordisk and Eli Lilly to enhance its competitive advantage in the GLP-1 space [7][8] - LifeMD plans to invest in growth for women's health and behavioral health offerings, which are expected to become significant revenue streams [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about 2026, anticipating significant growth driven by better pricing for branded therapies and increased insurance coverage [28][34] - The competitive landscape in the weight management category has intensified, but LifeMD remains focused on high-quality offerings [7][56] - The anticipated approval of the Wegovy pill is expected to be a major catalyst for business growth [9][56] Other Important Information - The company divested its majority interest in WorkSimpli, strengthening its balance sheet and allowing it to focus on its core healthcare platform [5][17] - LifeMD has secured regulatory approval for its non-sterile 503A compounding pharmacy, which will enhance its ability to produce personalized medications [5][11] Q&A Session Summary Question: Can you talk about the mix of telehealth product revenue, especially in weight loss? - Weight management still constitutes more than 50% of total revenue, with a slight sequential decline in subscriber base [24][25] Question: What portion of your revenue is insurance-covered versus cash-pay? - Management is not prepared to provide an exact percentage but noted that a significant portion of patients do not continue due to lack of insurance coverage [34][37] Question: How much of the growth in RexMD is driven by men's HRT versus ED? - About 8,000 of the 10,000 new members came from the sexual health business, primarily ED [61] Question: What drove the decline in telehealth gross margin? - The decline was attributed to a shift towards branded products, which do not carry the same fulfillment fees as personalized compounds [62][63] Question: What impact do you expect from the new consumer-facing app and website? - The new app is expected to significantly enhance cross-selling ability and improve customer retention [75][76] Question: What is the anticipated timeline for reaching 50-state coverage for the 503A pharmacy? - The company expects to be licensed in 35 states within 60-90 days and aims for full coverage shortly thereafter [80][81]

Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, alleging misleading representations regarding its financial health and growth prospects, following a significant stock price decline after its earnings report in August 2025 [1][4]. Summary by Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., focuses on the period from May 7, 2025, to August 5, 2025, claiming that LifeMD made false statements, particularly during its first-quarter results announcement on May 6, 2025, when it raised its full-year revenue and adjusted EBITDA guidance [2][4]. - The complaint asserts that LifeMD's optimistic outlook regarding its competitive position in virtual obesity care and performance from its RexMD brand was misleading, as it did not disclose significant operational challenges [2][3]. Financial Performance and Stock Impact - LifeMD's issues included rising customer acquisition costs in its RexMD segment and a higher-than-expected refund rate in its weight management business, which were not disclosed to investors [3]. - The situation escalated on August 5, 2025, when LifeMD reported second-quarter results that missed revenue and earnings per share estimates, leading to a reduction in its full-year guidance. The stock price subsequently dropped by over 44% the following day [4]. Investor Actions - The lawsuit provides an opportunity for investors who experienced substantial losses during the specified period to seek recovery [5]. - Hagens Berman, the law firm investigating these claims, is looking into whether LifeMD was aware of but failed to disclose key operational issues [6].

Core Points - The Gross Law Firm has issued a notice to shareholders of LifeMD, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose important information during the class period from May 7, 2025, to August 5, 2025 [1] - Allegations include that LifeMD's competitive position was overstated, and that the company did not properly account for rising customer acquisition costs, particularly in its RexMD segment and for obesity treatment drugs [1] - The deadline for shareholders to register for the class action and seek lead plaintiff status is October 27, 2025 [2] Company Specifics - LifeMD, Inc. is facing allegations of materially false and misleading statements regarding its business operations and prospects, which may have led to an artificial inflation of its stock price [1] - The lawsuit highlights concerns over the company's guidance for 2025, which was deemed reckless given the unaccounted rising customer acquisition costs [1] Legal Context - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3] - Shareholders who register will be enrolled in a portfolio monitoring system to receive updates on the case [2]

Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, alleging misleading statements regarding its financial health and growth prospects, particularly following a significant stock price decline after its earnings report in August 2025 [1][4]. Summary by Relevant Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., covers the period from May 7, 2025, to August 5, 2025, claiming that LifeMD made false statements, especially on May 6, 2025, when it reported first-quarter results and raised its full-year revenue and adjusted EBITDA guidance [2]. - The complaint asserts that LifeMD's optimistic outlook regarding its competitive position in virtual obesity care and performance from its RexMD brand was misleading, as it did not disclose significant operational challenges [2][3]. Financial Performance and Stock Impact - LifeMD's stock price fell over 44% the day after the company announced its second-quarter results on August 5, 2025, which missed revenue and earnings per share estimates and included a reduction in full-year guidance [4]. - During the earnings call, management attributed the poor performance to "temporary elevated customer acquisition costs" in the RexMD business and issues with patient refunds in its weight management offerings [4]. Investor Actions - Investors who suffered losses during the specified period are encouraged to participate in the lawsuit as a means to recover damages [5]. - Hagens Berman, the law firm leading the investigation, is looking into whether LifeMD was aware of but failed to disclose key operational problems [6].

Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, alleging misleading representations regarding its financial health and growth prospects, following a significant stock price decline after its earnings report in August 2025 [1]. Summary by Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., covers the period from May 7, 2025, to August 5, 2025, claiming that LifeMD made false statements, particularly during its first-quarter results announcement on May 6, 2025, when it raised its full-year revenue and adjusted EBITDA guidance [2]. - The complaint asserts that LifeMD's optimistic outlook regarding its competitive position in virtual obesity care and the performance of its RexMD brand was misleading, as it did not disclose significant operational challenges [2]. Operational Challenges - The lawsuit highlights that LifeMD faced increasing customer acquisition costs in its RexMD segment and a higher-than-expected refund rate in its weight management business, which were not disclosed to investors [3]. Stock Price Impact - The alleged misleading information came to light on August 5, 2025, when LifeMD reported second-quarter results that missed revenue and earnings per share estimates, leading to a reduction in its full-year guidance. The company's management attributed this to "temporary elevated customer acquisition costs" and refund issues, resulting in a stock price drop of over 44% the following day [4]. Investor Recovery - For investors who incurred significant losses during the specified period, the lawsuit presents an opportunity for potential recovery of damages [5]. Investigation by Hagens Berman - Hagens Berman, a national plaintiffs' rights firm, is investigating the claims against LifeMD, focusing on whether the company was aware of but failed to disclose key operational issues [6].

Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, alleging misleading representations regarding its financial health and growth prospects, following a significant stock price decline after its earnings report in August 2025 [1]. Summary by Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., covers the period from May 7, 2025, to August 5, 2025, claiming that LifeMD made false statements, particularly during its first-quarter results announcement on May 6, 2025, when it raised its full-year revenue and adjusted EBITDA guidance [2]. - The complaint asserts that LifeMD's optimistic outlook, which highlighted a "category-defining competitive moat" in virtual obesity care and strong performance from its RexMD brand, was misleading as it did not disclose significant operational challenges [2]. Operational Challenges - The lawsuit contends that LifeMD faced increasing customer acquisition costs in its RexMD segment and a higher-than-expected refund rate in its weight management business, which were not disclosed to investors [3]. Stock Price Impact - The alleged misleading information came to light on August 5, 2025, when LifeMD reported second-quarter results that missed revenue and earnings per share estimates, leading to a reduction in its full-year guidance. The management attributed this to "temporary elevated customer acquisition costs" and refund issues, resulting in a stock price drop of over 44% the following day [4]. Investor Recovery - For investors who incurred significant losses during the specified period, the lawsuit presents an opportunity for potential recovery of damages [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased LifeMD, Inc. securities between May 7, 2025, and August 5, 2025, of the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who bought LifeMD securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by October 27, 2025 [3]. - The lawsuit claims that defendants made materially false and misleading statements regarding LifeMD's competitive position and financial guidance, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, alleging misleading representations regarding its financial health and growth prospects, following a significant stock price decline after its earnings report in August [1][4]. Summary by Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., focuses on the period from May 7, 2025, to August 5, 2025, claiming that LifeMD made false statements, particularly during its first-quarter results announcement on May 6, 2025, when it raised its revenue and adjusted EBITDA guidance [2][4]. - The complaint asserts that LifeMD's optimistic outlook regarding its competitive position in virtual obesity care and performance from its RexMD brand was misleading, as it did not disclose significant operational challenges [2][3]. Financial Performance and Stock Impact - LifeMD's alleged deception became apparent on August 5, 2025, when it reported second-quarter results that missed revenue and earnings per share estimates, leading to a reduction in its full-year guidance. The management attributed this to "temporary elevated customer acquisition costs" and issues with patient refunds [4]. - Following the earnings announcement, LifeMD's stock price dropped by over 44% the next day, reflecting investor reaction to the disclosed operational issues [4]. Investor Recovery Opportunity - The lawsuit provides an opportunity for investors who suffered substantial losses during the specified period to seek recovery of damages [5]. - Hagens Berman, the firm investigating these claims, is looking into whether LifeMD was aware of but failed to disclose key operational problems [6].

Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, Inc. and its executives, alleging that the company misrepresented its financial health and growth, leading to a significant decline in stock price in August 2025 [1][6]. Summary by Relevant Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., covers the period from May 7, 2025, to August 5, 2025, and seeks to recover damages for investors who incurred substantial losses during this timeframe [2][8]. Financial Performance and Allegations - On May 6, 2025, LifeMD reported strong first-quarter results and raised its full-year revenue and adjusted EBITDA guidance, claiming a "category-defining competitive moat" in virtual obesity care and strong performance from its RexMD brand [5]. - The lawsuit argues that this optimistic outlook was misleading due to undisclosed ongoing business challenges, including rising customer acquisition costs and high patient refund rates [6][9]. Stock Price Impact - Following the announcement of disappointing second-quarter results on August 5, 2025, which included missed revenue and earnings estimates and a reduction in full-year guidance, LifeMD's stock price fell by over 44% the next day [7][6]. Investigation and Whistleblower Information - Hagens Berman, a national plaintiffs' rights firm, is investigating the claims on behalf of affected investors, focusing on whether LifeMD's management accurately represented its financial guidance amid rising costs and refund issues [10][11]. - Whistleblowers with non-public information regarding LifeMD are encouraged to assist in the investigation, with potential rewards under the SEC Whistleblower program [11].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of LifeMD, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its competitive position and financial guidance during a specified class period [1][2]. Summary by Relevant Sections Allegations - The complaint claims that during the class period from May 7, 2025, to August 5, 2025, LifeMD's defendants overstated the company's competitive position [1]. - It is alleged that the defendants were reckless in raising LifeMD's 2025 guidance without properly accounting for increasing customer acquisition costs in the RexMD segment and related to obesity treatment drugs like Wegovy and Zepbound [1]. - As a result, the statements made by the defendants regarding LifeMD's business, operations, and prospects were materially false and misleading [1]. Next Steps for Shareholders - Shareholders who purchased shares of LFMD during the specified timeframe are encouraged to register for the class action by October 25, 2025, to potentially become lead plaintiffs [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [2]. Firm's Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].